Breaking News

KRTX

Karuna Therapeutics

20
Jun

05/08/23 Mizuho: Karuna Therapeutics price target raised to $274 from $270 at Mizuho

03/28/23 H.C. Wainwright: Karuna Therapeutics price target lowered to $300 from $320 at H.C. Wainwright

03/08/23 Cantor Fitzgerald: Karuna initiated with Neutral, $214 target at Cantor Fitzgerald

03/07/23 Cantor Fitzgerald: Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Karuna Therapeutics price target raised to $274 from $270 at Mizuho » 06:43 05/08/23 05/08 06:43 05/08/23 06:43 KRTX Karuna Therapeutics $220.09 / +13.785 (+6.68%) Mizuho analyst Graig… Mizuho analyst Graig Suvannavejh raised the firm's price target on Karuna Therapeutics to $274 from $270 and keeps a Buy rating on the shares. The analyst updated the company's model post the Q1 results. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $220.09 / +13.785 (+6.68%) 05/04/23 Karuna Therapeutics sees cash, securities, sufficient through end of 2026 03/23/23 Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB KRTX Karuna Therapeutics $220.09 / +13.785 (+6.68%) 03/28/23 H.C. Wainwright Karuna Therapeutics price target lowered to $300 from $320 at H.C. Wainwright 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo KRTX Karuna Therapeutics $220.09 / +13.785 (+6.68%) 05/04/23 Karuna Therapeutics reports Q1 EPS , consensus ($2.73) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 22 Mar 10 Aug KRTX Karuna Therapeutics $220.09 / +13.785 (+6.68%) 03/24/23 Biotech Alert: Searches spiking for these stocks today 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 06/20/23 Karuna Therapeutics, Inc.

Over a month ago
Hot Stocks	Karuna Therapeutics sees cash, securities, sufficient through end of 2026 06:44 05/04/23 05/04 06:44 05/04/23 06:44 KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/23/23 Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/28/23 H.C. Wainwright Karuna Therapeutics price target lowered to $300 from $320 at H.C. Wainwright 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 05/04/23 Karuna Therapeutics reports Q1 EPS , consensus ($2.73) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 22 Mar 10 Aug KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/24/23 Biotech Alert: Searches spiking for these stocks today 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 05/04/23 Karuna Therapeutics - KRTX 06/20/23 Karuna Therapeutics, Inc.
Earnings	Karuna Therapeutics reports Q1 EPS , consensus ($2.73) » 06:43 05/04/23 05/04 06:43 05/04/23 06:43 KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) Reports Q1 revenue $654K… Reports Q1 revenue $654K vs. no revenue last year. "We've had a very strong start to the year," said Bill Meury, CEO. "We announced positive data from EMERGENT-3, our third consecutive registrational trial of KarXT in schizophrenia, which further reinforces KarXT's potential to be a completely novel and differentiated treatment for people living with schizophrenia. On the regulatory front, we remain on track to submit our NDA mid-year - specifically the third quarter - following an encouraging pre-NDA meeting with the FDA last month. We've also made significant progress advancing EMERGENT-4 and 5, our Phase 3 open-label trials evaluating the long-term safety of KarXT in schizophrenia, which will provide valuable information for both the NDA and medical education pre- and post-launch, with data to share next year. As we continue to build the infrastructure to support the potential commercialization of KarXT in schizophrenia, we maintain a sharp focus on the execution of our ARISE program evaluating KarXT as an adjunctive treatment for schizophrenia, with anticipated topline data from the Phase 3 ARISE trial in the second half of 2024, as we activate additional sites to support recruitment in the study. ---Beyond KarXT, we continue to grow our pipeline both organically and inorganically, most notably with our exclusive global in-license agreement for TRPC4/5 inhibitors for the treatment of mood and anxiety disorders announced in February, and we look forward to sharing next steps in the program later this year." ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/23/23 Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/28/23 H.C. Wainwright Karuna Therapeutics price target lowered to $300 from $320 at H.C. Wainwright 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 22 Mar 10 Aug KRTX Karuna Therapeutics $210.46 / +8.62 (+4.27%) 03/24/23 Biotech Alert: Searches spiking for these stocks today 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 05/04/23 Karuna Therapeutics - KRTX 06/20/23 Karuna Therapeutics, Inc.
Recommendations	Karuna Therapeutics price target lowered to $300 from $320 at H.C. Wainwright » 06:14 03/28/23 03/28 06:14 03/28/23 06:14 KRTX Karuna Therapeutics $185.71 / +3.58 (+1.97%) H.C. Wainwright analyst… H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Karuna Therapeutics to $300 from $320 and keeps a Buy rating on the shares. The analyst expects Karuna to file for approval of KarXT in mid-2023, with possible approval in the second half of 2024. It cites equity dilution for the target drop. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly KRTX Karuna Therapeutics $185.71 / +3.58 (+1.97%) 03/23/23 Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 KRTX Karuna Therapeutics $185.71 / +3.58 (+1.97%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS KRTX Karuna Therapeutics $185.71 / +3.58 (+1.97%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) 22 Mar 10 Aug KRTX Karuna Therapeutics $185.71 / +3.58 (+1.97%) 03/24/23 Biotech Alert: Searches spiking for these stocks today 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday
On The Fly	Biotech Alert: Searches spiking for these stocks today » 10:50 03/24/23 03/24 10:50 03/24/23 10:50 CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) , APTX Aptinyx / + , MCRB Seres Therapeutics $5.64 / -0.045 (-0.79%) , ARRY Array Technologies $19.10 / -0.71 (-3.58%) , KRTX Karuna Therapeutics $175.73 / -0.28 (-0.16%) , RPRX Royalty Pharma $34.74 / -0.07 (-0.20%) , PRTC PureTech Health $27.65 / -0.09 (-0.32%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RPRX PRTC MCRB KRTX CDTX ARRY APTX RPRX Royalty Pharma $34.74 / -0.07 (-0.20%) 03/23/23 PureTech Health sells interest in KarXT to Royalty Pharma for up to $500M 03/01/23 Royalty Pharma appoints Ashwin Pai as EVP, investments 02/15/23 Royalty Pharma sees FY23 adjusted cash receipts view $2.375B-$2.475B PRTC PureTech Health $27.65 / -0.09 (-0.32%) 02/14/23 PureTech Health to advance LYT-300 for treatment of anxiety disorders and PPD 01/12/23 PureTech Health PLC (ADR) trading resumes MCRB Seres Therapeutics $5.64 / -0.045 (-0.79%) 02/14/23 Seres SER-109 data for rCDI published, PDUFA action date set for April 26 02/08/23 Seres Therapeutics initiates enrollment in Cohort 2 in SER-155 trial 01/13/23 Seres Therapeutics reports inducement grants under Nasdaq listing rule 11/03/22 Cara Therapeutics appoints Lisa von Moltk to board of directors KRTX Karuna Therapeutics $175.73 / -0.28 (-0.16%) 03/23/23 Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) 03/22/23 Cidara Therapeutics and Melinta Therapeutics' Rezzayo approved by FDA 03/01/23 Cidara Therapeutics announces interim Phase 2a data of CD388 02/14/23 Cidara regains compliance with Nasdaq minimum bid price requirement 02/01/23 Cidara Therapeutics, WuXi XDC expand collaboration for CD73 program ARRY Array Technologies $19.10 / -0.71 (-3.58%) 03/15/23 Array Technologies reschedules earnings, needs more time to file annual report 03/03/23 Avangrid announces intent to deploy more than $30M in solar trackers from Array 01/30/23 Array Technologies names Manning as Chief Operations Officer 11/08/22 Array Technologies appoints Jokinen to board of directors APTX Aptinyx / + 02/27/23 Aptinyx trading resumes 02/27/23 Aptinyx to resume trading at 4:35pm E.T. 02/27/23 Aptinyx says Phase 2 Study of NYX-458 did not demonstrate sufficient efficacy 02/27/23 Aptinyx trading halted, news pending CDTX APTX MCRB ARRY KRTX RPRX PRTC CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) 03/21/23 Cantor Fitzgerald Cantor reiterates Overweight ratings on anti-fungal stocks Cidara, Scynexis 01/25/23 H.C. Wainwright Cidara panel vote greatly increases approval chances, says H.C. Wainwright 05/12/22 H.C. Wainwright Cidara Therapeutics price target lowered to $6 from $7.50 at H.C. Wainwright APTX Aptinyx / + 03/07/23 H.C. Wainwright Aptinyx downgraded to Neutral from Buy at H.C. Wainwright 03/01/23 SVB Securities SVB Securities downgrades Aptinyx to Market Perform, lowers price target to 50c 03/01/23 SVB Securities Aptinyx downgraded to Market Perform from Outperform at SVB Securities 08/26/22 H.C. Wainwright Aptinyx price target lowered to $1 from $2 at H.C. Wainwright MCRB Seres Therapeutics $5.64 / -0.045 (-0.79%) 03/21/23 Canaccord Seres Therapeutics price target raised to $15 from $11 at Canaccord 03/08/23 Canaccord Seres Therapeutics price target lowered to $11 from $17 at Canaccord 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 12/20/22 Piper Sandler Piper Sandler names three top biotechnology picks for 2023 ARRY Array Technologies $19.10 / -0.71 (-3.58%) 03/22/23 Guggenheim Array Technologies price target lowered to $35 from $36 at Guggenheim 03/09/23 Citi Array Technologies initiated with a Neutral at Citi 03/07/23 Piper Sandler Array Technologies price target lowered to $26 from $28 at Piper Sandler 03/01/23 Scotiabank Array Technologies initiated with an Outperform at Scotiabank KRTX Karuna Therapeutics $175.73 / -0.28 (-0.16%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS RPRX Royalty Pharma $34.74 / -0.07 (-0.20%) 09/06/22 Morgan Stanley Biogen named a 'Catalyst Driven Idea' at Morgan Stanley 07/28/22 Citi Royalty Pharma price target raised to $60 from $50 at Citi 07/14/22 Tigress Financial Royalty Pharma price target raised to $57 from $52 at Tigress Financial 06/13/22 UBS Royalty Pharma initiated with a Buy at UBS PRTC PureTech Health $27.65 / -0.09 (-0.32%) 08/26/22 Piper Sandler PureTech Health price target raised to $44 from $37 at Piper Sandler 08/25/22 Piper Sandler PureTech Health price target raised to $44 from $37 at Piper Sandler 06/14/22 Piper Sandler PureTech Health price target lowered to $37 from $72 at Piper Sandler RPRX MCRB KRTX CDTX ARRY APTX RPRX Royalty Pharma $34.74 / -0.07 (-0.20%) 03/15/23 Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B 02/15/23 Royalty Pharma reports Q4 revenue $566M vs $576M last year 11/08/22 Royalty Pharma raises FY22 adjusted cash receipts view to $2.75M-$2.8M 11/08/22 Royalty Pharma reports Q3 revenue $573M, consensus $587.17M MCRB Seres Therapeutics $5.64 / -0.045 (-0.79%) 03/07/23 Seres Therapeutics reports 2022 revenue $7.13M, consensus $10.7M 11/02/22 Seres Therapeutics reports Q3 EPS (49c), consensus (47c) KRTX Karuna Therapeutics $175.73 / -0.28 (-0.16%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) 03/23/23 Cidara Therapeutics reports Q4 EPS (19c), consensus (17c) 11/03/22 Cidara Therapeutics reports Q3 EPS 17c, consensus 18c ARRY Array Technologies $19.10 / -0.71 (-3.58%) 03/21/23 Array Technologies sees FY23 adjusted EPS 75c-85c, consensus 78c 03/21/23 Array Technologies reports Q4 adjusted EPS 10c, consensus 8c 03/21/23 Notable companies reporting after market close 03/02/23 Array Technologies sees 2023 adjusted EPS 75c-85c, consensus 95c APTX Aptinyx / + 11/08/22 Aptinyx reports Q3 EPS (23c), consensus (24c) 22 Mar 03 Mar 10 Aug PRTC ARRY PRTC PureTech Health $27.65 / -0.09 (-0.32%) 10/06/22 PureTech Health takeover rumor highlighted in Betaville blog ARRY Array Technologies $19.10 / -0.71 (-3.58%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports RPRX MCRB KRTX CDTX ARRY RPRX Royalty Pharma $34.74 / -0.07 (-0.20%) 03/15/23 Fly Intel: Pre-market Movers MCRB Seres Therapeutics $5.64 / -0.045 (-0.79%) 10/28/22 Biotech Alert: Searches spiking for these stocks today KRTX Karuna Therapeutics $175.73 / -0.28 (-0.16%) 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) 03/23/23 Biotech Alert: Searches spiking for these stocks today ARRY Array Technologies $19.10 / -0.71 (-3.58%) 03/22/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street This Morning 03/21/23 Fly Intel: After-Hours Movers 03/16/23 What You Missed On Wall Street On Thursday 04/03/23 The Future of Oncology Virtual Symposium 04/26/23 PDUFA Date for SER-109 CDTX ARRY CDTX Cidara Therapeutics $1.25 / -0.19 (-13.19%) 03/23/23 Cidara Therapeutics options imply 21.4% move in share price post-earnings 03/17/23 Cidara Therapeutics options imply 29.3% move in share price post-earnings 03/13/23 Cidara Therapeutics options imply 14.0% move in share price post-earnings 03/06/23 Cidara Therapeutics options imply 20.0% move in share price post-earnings ARRY Array Technologies $19.10 / -0.71 (-3.58%) 03/21/23 Array Technologies options imply 4.0% move in share price post-earnings 03/20/23 Array Technologies call volume above normal and directionally bullish 03/15/23 Array Technologies options imply 6.5% move in share price post-earnings 03/06/23 Array Technologies call volume above normal and directionally bullish
Hot Stocks	Royalty Pharma acquires interest in PureTech's royalty in Karuna's KarXT » 07:09 03/23/23 03/23 07:09 03/23/23 07:09 RPRX Royalty Pharma $34.87 / -0.305 (-0.87%) , PRTC PureTech Health $25.00 / -1.7 (-6.37%) , KRTX Karuna Therapeutics $169.57 / +8.375 (+5.20%) Royalty Pharma (RPRX) and… Royalty Pharma (RPRX) and PureTech Health (PRTC) announced that Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' (KRTX) KarXT for up to $500M with $100M in cash up front and up to $400M in additional payments contingent on the achievement of certain regulatory and commercial milestones. As part of this transaction, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments. PureTech retains its 3.1% equity ownership in Karuna1. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly RPRX PRTC KRTX RPRX Royalty Pharma $34.87 / -0.305 (-0.87%) 03/23/23 PureTech Health sells interest in KarXT to Royalty Pharma for up to $500M 03/01/23 Royalty Pharma appoints Ashwin Pai as EVP, investments 02/15/23 Royalty Pharma sees FY23 adjusted cash receipts view $2.375B-$2.475B 01/09/23 Royalty Pharma provides business update, outlook PRTC PureTech Health $25.00 / -1.7 (-6.37%) 02/14/23 PureTech Health to advance LYT-300 for treatment of anxiety disorders and PPD 01/12/23 PureTech Health PLC (ADR) trading resumes 01/12/23 PureTech Health PLC (ADR) trading halted, volatility trading pause KRTX Karuna Therapeutics $169.57 / +8.375 (+5.20%) 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 01/31/23 Karuna Therapeutics appoints William Kane as Chief Commercial Officer RPRX PRTC KRTX RPRX Royalty Pharma $34.87 / -0.305 (-0.87%) 09/06/22 Morgan Stanley Biogen named a 'Catalyst Driven Idea' at Morgan Stanley 07/28/22 Citi Royalty Pharma price target raised to $60 from $50 at Citi 07/14/22 Tigress Financial Royalty Pharma price target raised to $57 from $52 at Tigress Financial 06/13/22 UBS Royalty Pharma initiated with a Buy at UBS PRTC PureTech Health $25.00 / -1.7 (-6.37%) 08/26/22 Piper Sandler PureTech Health price target raised to $44 from $37 at Piper Sandler 08/25/22 Piper Sandler PureTech Health price target raised to $44 from $37 at Piper Sandler 06/14/22 Piper Sandler PureTech Health price target lowered to $37 from $72 at Piper Sandler KRTX Karuna Therapeutics $169.57 / +8.375 (+5.20%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS RPRX KRTX RPRX Royalty Pharma $34.87 / -0.305 (-0.87%) 03/15/23 Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B 02/15/23 Royalty Pharma reports Q4 revenue $566M vs $576M last year 11/08/22 Royalty Pharma raises FY22 adjusted cash receipts view to $2.75M-$2.8M 11/08/22 Royalty Pharma reports Q3 revenue $573M, consensus $587.17M KRTX Karuna Therapeutics $169.57 / +8.375 (+5.20%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) 22 Mar 10 Aug PRTC PRTC PureTech Health $25.00 / -1.7 (-6.37%) 10/06/22 PureTech Health takeover rumor highlighted in Betaville blog RPRX KRTX RPRX Royalty Pharma $34.87 / -0.305 (-0.87%) 03/15/23 Fly Intel: Pre-market Movers KRTX Karuna Therapeutics $169.57 / +8.375 (+5.20%) 03/22/23 Biotech Alert: Searches spiking for these stocks today 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning
On The Fly	Biotech Alert: Searches spiking for these stocks today » 10:37 03/22/23 03/22 10:37 03/22/23 10:37 CNTB Connect Biopharma $1.11 / -0.06 (-5.13%) , KRTX Karuna Therapeutics $177.46 / +16.265 (+10.09%) , IBIO iBio $2.38 / -0.085 (-3.45%) , ACER Acer Therapeutics / + These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options KRTX IBIO CNTB ACER KRTX Karuna Therapeutics $177.46 / +16.265 (+10.09%) 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 01/31/23 Karuna Therapeutics appoints William Kane as Chief Commercial Officer IBIO iBio $2.38 / -0.085 (-3.45%) 01/05/23 iBio announces USPTO issued patent on AI-engineered epitope discovery 12/02/22 iBio announces resignation of CEO Thomas Isett 11/03/22 iBio seeking to divest its contract development, manufacturing organization 09/27/22 iBio dives 34% to 21c per share after reporting FY22 preliminary revenue CNTB Connect Biopharma $1.11 / -0.06 (-5.13%) 03/19/23 Connect Biopharma presents data from Stage 1 of CBP-201 China trial 03/17/23 Connect Biopharma jumps 41% to $1.55 after positive Phase 2b CBP-201 data 03/17/23 Connect Biopharma Phase 2b CBP-201 data showed improvement in AD signs 12/30/22 Connect Biopharma sees cash runway into 2025 ACER Acer Therapeutics / + 03/22/23 Acer Therapeutics: Data presented at SIMD on Urea Cycle Disorders 03/17/23 Acer reports Phase 2 trial of ACER-801 did not achieve statistical significance 03/15/23 Acer Therapeutics announces presentation at upcoming meeting for SIMD 02/13/23 Acer Therapeutics announces full enrollment in Phase 2a trial of ACER-801 CNTB KRTX IBIO ACER CNTB Connect Biopharma $1.11 / -0.06 (-5.13%) 09/14/22 Piper Sandler Connect Biopharma price target raised to $1.75 from $1.50 at Piper Sandler 06/02/22 Cantor Fitzgerald Connect Biopharma initiated with an Overweight at Cantor Fitzgerald 05/05/22 Piper Sandler Connect Biopharma downgraded to Neutral from Overweight at Piper Sandler KRTX Karuna Therapeutics $177.46 / +16.265 (+10.09%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS IBIO iBio $2.38 / -0.085 (-3.45%) 02/15/23 JMP Securities iBio downgraded to Market Perform at JMP on CDMO and IBIO-101 questions 02/15/23 JMP Securities iBio downgraded to Market Perform from Outperform at JMP Securities 10/06/22 Cantor Fitzgerald iBio downgraded to Neutral from Overweight at Cantor Fitzgerald ACER Acer Therapeutics / + KRTX IBIO ACER KRTX Karuna Therapeutics $177.46 / +16.265 (+10.09%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) IBIO iBio $2.38 / -0.085 (-3.45%) 09/27/22 iBio reports FY22 revenue $2.4M, two estimates, $2.55M ACER Acer Therapeutics / + 11/14/22 Acer Therapeutics reports Q3 EPS (31c), consensus (68c) 22 Mar 07 Dec 10 Aug KRTX IBIO CNTB ACER KRTX Karuna Therapeutics $177.46 / +16.265 (+10.09%) 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning IBIO iBio $2.38 / -0.085 (-3.45%) 12/09/22 Biotech Alert: Searches spiking for these stocks today 09/27/22 Fly Intel: After-Hours Movers CNTB Connect Biopharma $1.11 / -0.06 (-5.13%) 03/22/23 Biotech Alert: Searches spiking for these stocks today 10/06/22 Biotech Alert: Searches spiking for these stocks today ACER Acer Therapeutics / + 03/20/23 Biotech Alert: Searches spiking for these stocks today 12/27/22 Fly Intel: Pre-market Movers 12/05/22 Fly Insider: Vapotherm, Applovin among week's notable insider trades IBIO IBIO iBio $2.38 / -0.085 (-3.45%) 03/22/23 Largest borrow rate increases among liquid names 03/20/23 Largest borrow rate increases among liquid names 03/13/23 Largest borrow rate increases among liquid names 03/10/23 Largest borrow rate increases among liquid names
Syndicate	Karuna Therapeutics 2.48M share Secondary priced at $161.33 » 20:26 03/21/23 03/21 20:26 03/21/23 20:26 KRTX Karuna Therapeutics $161.19 / -21.09 (-11.57%) The deal priced at last… The deal priced at last closing price of $161.33. Goldman Sachs is acting as lead book running manager for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly KRTX Karuna Therapeutics $161.19 / -21.09 (-11.57%) 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 01/31/23 Karuna Therapeutics appoints William Kane as Chief Commercial Officer KRTX Karuna Therapeutics $161.19 / -21.09 (-11.57%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS KRTX Karuna Therapeutics $161.19 / -21.09 (-11.57%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) 22 Mar 10 Aug KRTX Karuna Therapeutics $161.19 / -21.09 (-11.57%) 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Syndicate	Karuna Therapeutics announces $400M offering of common stock » 16:44 03/20/23 03/20 16:44 03/20/23 16:44 KRTX Karuna Therapeutics $182.28 / -9.01 (-4.71%) Karuna Therapeutics… Karuna Therapeutics announced that it has commenced an underwritten public offering of $400M of its common stock. Goldman Sachs & Co., J.P. Morgan Securities, and Morgan Stanley & Co. are acting as joint book-running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly KRTX Karuna Therapeutics $182.28 / -9.01 (-4.71%) 03/20/23 Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 01/31/23 Karuna Therapeutics appoints William Kane as Chief Commercial Officer KRTX Karuna Therapeutics $182.28 / -9.01 (-4.71%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS KRTX Karuna Therapeutics $182.28 / -9.01 (-4.71%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) 10 Aug KRTX Karuna Therapeutics $182.28 / -9.01 (-4.71%) 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Karuna Therapeutics announces 'positive' results from Phase 3 EMERGENT-3 trial » 06:34 03/20/23 03/20 06:34 03/20/23 06:34 KRTX Karuna Therapeutics $191.61 / +2.27 (+1.20%) Karuna Therapeutics… Karuna Therapeutics announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in Positive and Negative Syndrome Scale total score compared to placebo at Week 5. Consistent with prior trials, KarXT demonstrated an early and sustained statistically significant reduction of symptoms from Week 2 through the end of the trial as assessed by PANSS total score. The NDA submission for KarXT in schizophrenia will incorporate the efficacy and safety data from the three placebo-controlled registrational trials, EMERGENT-1, EMERGENT-2, and EMERGENT-3, in addition to long-term safety data from the ongoing EMERGENT-4 and EMERGENT-5 trials. The company is on track to submit an NDA to the FDA in mid-2023, with a potential launch in the second half of 2024, if approved. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly KRTX Karuna Therapeutics $191.61 / +2.27 (+1.20%) 03/10/23 Karuna says maintains 'de minimis amount' of cash, equivalents with SVB 02/02/23 Karuna Therapeutics signing exclusive global license agreement for TRPC4/5 01/31/23 Karuna Therapeutics appoints William Kane as Chief Commercial Officer 12/06/22 Karuna Therapeutics names Bill Meury as CEO, succeeding Steve Paul, M.D. KRTX Karuna Therapeutics $191.61 / +2.27 (+1.20%) 03/08/23 Cantor Fitzgerald Karuna initiated with Neutral, $214 target at Cantor Fitzgerald 03/07/23 Cantor Fitzgerald Karuna Therapeutics initiated with a Neutral at Cantor Fitzgerald 03/02/23 Wells Fargo Karuna Therapeutics price target lowered to $257 from $262 at Wells Fargo 01/27/23 UBS Karuna Therapeutics initiated with a Neutral at UBS KRTX Karuna Therapeutics $191.61 / +2.27 (+1.20%) 02/23/23 Karuna Therapeutics reports Q4 EPS ($2.22), consensus ($2.25) 11/03/22 Karuna Therapeutics reports Q3 EPS ($2.38), consensus ($2.13) 10 Aug KRTX Karuna Therapeutics $191.61 / +2.27 (+1.20%) 03/17/23 Sell these stocks now, proven algorithm says 11/01/22 What You Missed On Wall Street On Tuesday 11/01/22 What You Missed On Wall Street This Morning 11/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial